Flavio Solca

Flavio Solca currently serves as Chief Scientific Officer at NBE-Therapeutics AG since October 2021. Prior to this role, Flavio Solca held several positions at Boehringer Ingelheim RCV, starting as Group Leader and advancing to Head Of Department Late Stage Cancer Research from March 2002 to the present. Flavio Solca was also Laboratory Head in Pharmacology at Boehringer Ingelheim from June 1995 to March 2002. Earlier in the career, Flavio Solca gained valuable experience as a Postdoctoral Research Fellow at the University of Washington and ZLF University Hospital Basel, and as a PhD student and Masters student at Biozentrum, University of Basel.